EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non–small cell lung cancer

Sophie O'Keefe, Qiwei Wang

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci191094 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Sophie O'Keefe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Acetyl-CoA C-Acetyltransferase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non–small cell lung cancer (NSCLC), the most common type of lung cancer, remains a leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have emerged as a promising therapy for NSCLC but only benefit a subset of patients. In this issue of the JCI , Jiao et al. revealed that acetyl-CoA acetyltransferase 1 (ACAT1) limited the efficacy of ICIs in NSCLC by impeding tertiary lymphoid structures (TLS) in the tumor microenvironment (TME). Targeting ACAT1 in tumor cells reduced mitochondrial hypersuccinylation and oxidative stress, enhancing TLS abundance and improving the efficacy of ICIs in preclinical murine models of NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyAcetyl-CoA C-AcetyltransferaseTertiary Lymphoid StructuresTumor MicroenvironmentNeoplasm ProteinsHumansAnimalsMice

Substanzen

Acetyl-CoA C-AcetyltransferaseACAT1 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, USA.
  • Beirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

Zitieren

APA

O'Keefe, S., & Wang, Q. (2025). ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non–small cell lung cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci191094

Vancouver

O'Keefe S, Wang Q. ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non–small cell lung cancer. Journal of Clinical Investigation. 2025. doi:10.1172/jci191094

BibTeX
@article{OKeefe2025,
  author = {O'Keefe, Sophie and Wang, Qiwei},
  title = {ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non–small cell lung cancer},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci191094}
}
Kostenlos starten →